STRATEGIES TO COMBAT MULTIDRUG RESISTANCE OF CANCER
DOI:
https://doi.org/10.56782/pps.86Keywords:
ATP–binding cassette [ABC] transporters, P – glycoprotein, multidrug resistance, nanoparticlesAbstract
Multidrug resistance (MDR) is a major impediment to the success of cancer chemotherapy. Significant progress in the understanding of MDR came with the identification of MDR P-glycoprotein and other transporters whose overexpression was observed in some types of cancer cells. In addition, the MDR phenomenon has also become associated with other mechanisms, such as inhibition of apoptosis of cancer cells. Several strategies of combating MDR are described here. However, their clinical success has been limited, largely due to efficacy and/or safety issues. These issues can be resolved by the use of nanotechnology. Nanoparticles have the potential to improve the therapeutic index of currently available drugs by increasing drug efficacy, reducing their toxicity, and helping to achieve a therapeutically relevant steady-state level of the drug over extended periods of time. Nanoparticles may also improve the solubility and stability of the drug.
Downloads
References
Bamburowicz-Klimkowska M., Bogucka U., Szutowski M.M. „Funkcje transporterów typu ABC”, Biuletyn Wydziału Farmaceutycznego WUM, 2011, 3, 34-40
Baguley B.C. „Novel strategies for overcoming multidrug resistance in cancer”, BioDrugs, 2002, 16, 97-103 DOI: https://doi.org/10.2165/00063030-200216020-00003
Baguley B.C. „Multiple drug resistance mechanisms in cancer”, Molecular Biotechnology, 2010, 46, 308-316 DOI: https://doi.org/10.1007/s12033-010-9321-2
Nelson D.A., Tan T.T., Rabson A.B., Anderson D., Degenhardt K., White E. „Hypoxia and defective apoptosis drive genomic instability and tumorogenesis”, Genes & Development, 2004, 18(17), 2095-2107 DOI: https://doi.org/10.1101/gad.1204904
Yague E., Arance A., Kubitza L., O’Hare M., Jat P., Ogilvie C.M. „Ability to acquire drug resistance arises early during the tumorigenesis process”, Cancer Research, 2007, 67(3), 1130–1137 DOI: https://doi.org/10.1158/0008-5472.CAN-06-2574
Tredan O., Galmarini C.M., Patel K., Tannock I.F. „Drug resistance and the solid tumor microenvironment”, Journal of the National Cancer Institute, 2007, 99(19), 1441–1454 DOI: https://doi.org/10.1093/jnci/djm135
Maeda H., Fang J., Inutsuka T., Kitamoto Y. „Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications”, International Immunopharmacology, 2003, 3(3), 319–328 DOI: https://doi.org/10.1016/S1567-5769(02)00271-0
Harris A.L. „Hypoxia – a key regulatory factor in tumour growth”, Nature Reviews, 2002, 2(1), 38–47 DOI: https://doi.org/10.1038/nrc704
Cairns R., Papandreou I., Denko N. „Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment”, Molecular Cancer Research, 2006, 4(2), 61–70 DOI: https://doi.org/10.1158/1541-7786.MCR-06-0002
Kizaka-Kondoh S., Inoue M., Harada H., Hiraoka M. „Tumor hypoxia: a target for selective cancer therapy”, Cancer Science, 2003, 94(12), 1021–1028 DOI: https://doi.org/10.1111/j.1349-7006.2003.tb01395.x
Guppy M. „The hypoxic core: a possible answer to the cancer paradox”, Biochemical and Biophysical Research Communications, 2002, 299(4), 676–680 DOI: https://doi.org/10.1016/S0006-291X(02)02710-9
Comerford K.M., Wallace T.J., Karhausen J., Louis N.A., Montalto S.P., Colgan S.P. „Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene”, Cancer Research, 2002, 62(12), 3387–3394
Shannon A.M., Bouchier-Hayes D.J., Condron C.M., Toomey D. „Tumour hypoxia, chemotherapeutic resistance and hypoxiarelated therapies”, Cancer Treatment Reviews, 2003, 29(4), 297–307 DOI: https://doi.org/10.1016/S0305-7372(03)00003-3
Gillet J.P., Efferth T., Remacle J. „Chemotherapy-induced resistance by ATP-binding cassette transporter genes”, Biochimica et Biophysica Acta, 2007, 1775(2), 237–262 DOI: https://doi.org/10.1016/j.bbcan.2007.05.002
Chinn L.W., Kroetz D.L. „ABCB1 pharmacogenetics: progress, pitfalls, and promise” Clinical Pharmacology & Therapeutics, 2007, 81(2), 265–269 DOI: https://doi.org/10.1038/sj.clpt.6100052
Gottesman M.M., Fojo T., Bates S.E. „Multidrug resistance in cancer: role of ATP-dependent transporters”, Nature Reviews Cancer, 2002, 2(1), 48–58 DOI: https://doi.org/10.1038/nrc706
Kimura Y., Morita S., Matsuo M., Ueda K. „Mechanism of multidrug recognition by MDR1/ABCB1”, Cancer Science, 2007, 98(9), 1303–1310 DOI: https://doi.org/10.1111/j.1349-7006.2007.00538.x
Lemos C., Jansen G., Peters G.J. „Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors”, British Journal of Cancer, 2008, 98(5), 857–862 DOI: https://doi.org/10.1038/sj.bjc.6604213
Robey R.W., Polgar O., Deeken J., To K.W., Bates S.E. „ABCG2: determining its relevance in clinical drug resistance” Cancer Metastasis Reviews, 2007, 26(1), 39–57 DOI: https://doi.org/10.1007/s10555-007-9042-6
Paterson J.K., Shukla S., Black C.M., Tachiwada T., Garfield S., Wincovitch S. „Human ABCB6 localizes to both the outer mitochondrial membrane and the plasma membrane” Biochemistry, 2007, 46(33), 9443–9452 DOI: https://doi.org/10.1021/bi700015m
Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. „Targeting multidrug resistance in cancer” Nature Reviews Drug Discovery, 2006, 5(3), 219–34 DOI: https://doi.org/10.1038/nrd1984
Hanahan D., Weinberg R.A. „The hallmarks of cancer”, Cell, 2000, 100, 57–70 DOI: https://doi.org/10.1016/S0092-8674(00)81683-9
Sharma S.V., Gajowniczek P., Way I.P., Lee, D.Y., Jiang J., Yuza Y. „A common signaling cascade may underlie ‘‘addiction’’ to the Src, BCR-ABL, and EGF receptor oncogenes”, Cancer Cell, 2006, 10, 425–435 DOI: https://doi.org/10.1016/j.ccr.2006.09.014
Olson J.M., Hallahan A. R. „p38 MAP kinase: A convergence point in cancer therapy”, Trends in Molecular Medicine, 2004, 10, 125–129 DOI: https://doi.org/10.1016/j.molmed.2004.01.007
Hollt V., Kouba M., Dietel M., Vogt G. „Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by Pglycoprotein”, Biochemical Pharmacology, 1992, 43, 2601–2608 DOI: https://doi.org/10.1016/0006-2952(92)90149-D
Baer M.R. „Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720”, Blood, 2002, 100, 1224–1232 DOI: https://doi.org/10.1182/blood.V100.4.1224.h81602001224_1224_1232
Kolitz J.E. „Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621”, Journal of Clinical Oncology, 2004, 22, 4290–4301 DOI: https://doi.org/10.1200/JCO.2004.11.106
Guns E.S., Denyssevych T., Dixon R., Bally M.B., Mayer, L. „Drug interaction studies between paclitaxel (Taxol) and OC144-093 – a new modulator of MDR in cancer chemotherapy”, European Journal of Drug Metabolism and Pharmacokinetics, 2002,27, 119–126 DOI: https://doi.org/10.1007/BF03190426
Stewart A. „Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration”, Clinical Cancer Research, 6, 2000, 4186–4191
Minderman H., O’Loughlin K.L., Pendyala L., Baer M.R. „VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein”, Clinical Cancer Research, 2004, 10, 1826–1834 DOI: https://doi.org/10.1158/1078-0432.CCR-0914-3
Dantzig A.H., de Alwis D.P., Burgess M. „Considerations in the design and development of transport inhibitors as adjuncts to drug therapy”, Advanced Drug Delivery Reviews, 2003, 55, 133–150 DOI: https://doi.org/10.1016/S0169-409X(02)00175-8
Loo T.W., Clarke D.M. „Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism”, Journal of the National Cancer Institute, 2000, 92, 898–902 DOI: https://doi.org/10.1093/jnci/92.11.898
Zhou S., Lim L.Y., Chowbay B. „Herbal modulation of P-glycoprotein”, Drug Metabolism Reviews, 2004, 36, 57–104 DOI: https://doi.org/10.1081/DMR-120028427
Foster B.A., Coffey H.A., Morin M.J., Rastinejad, F. „Pharmacological rescue of mutant p53 conformation and function”, Science, 1999, 286, 2507–2510 DOI: https://doi.org/10.1126/science.286.5449.2507
Sebolt-Leopold J.S. „MEK inhibitors: A therapeutic approach to targeting the Ras-MAP kinase pathway in tumors” Current Pharmaceutical Design, 2004, 10, 1907–1914 DOI: https://doi.org/10.2174/1381612043384439
Serra V., Markman B., Scaltriti M., Eichhorn P.J., Valero V., Guzman M. „NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations” Cancer Research, 2008, 68, 8022–8030 DOI: https://doi.org/10.1158/0008-5472.CAN-08-1385
Nguyen M., Marcellus R.C., Roulston A., Watson M., Serfass L., Murthy Madiraju S.R. „Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1- mediated resistance to apoptosis”, Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19512–19517 DOI: https://doi.org/10.1073/pnas.0709443104
Nakanishi C., Toi M. „Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs”, Nature Reviews Cancer, 2005, 5, 297–309 DOI: https://doi.org/10.1038/nrc1588
Cleary J.M., Shapiro G.I. „Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer”, Current Oncology Reports, 2010, 12, 87–94 DOI: https://doi.org/10.1007/s11912-010-0091-6
Sharom F.J. „Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells”, Biochemical Pharmacology, 1999, 58, 571–586 DOI: https://doi.org/10.1016/S0006-2952(99)00139-2
Tarasova N.I. „Transmembrane inhibitors of P-glycoprotein, an ABC transporter” Journal of Medicinal Chemistry, 2005, 48, 3768–3775 DOI: https://doi.org/10.1021/jm049065t
Pawlak-Roblin C. „Inhibition of multidrug resistance by immunisation with synthetic Pglycoprotein- derived peptides”, European Journal of Cancer, 2004, 40, 606–613 DOI: https://doi.org/10.1016/j.ejca.2003.11.019
Scotto K.W. „Transcriptional regulation of ABC drug transporters”, Oncogene, 2003, 22, 7496–7511 DOI: https://doi.org/10.1038/sj.onc.1206950
Bartsevich V.V., Juliano R.L. „Regulation of the MDR1 gene by transcriptional repressors selected using peptide combinatorial libraries” Molecular Pharmacology, 2000, 58, 1–10 DOI: https://doi.org/10.1124/mol.58.1.1
Izquierdo M. „Short interfering RNAs as a tool for cancer gene therapy”, Cancer Gene Therapy, 2005, 12, 217-227 DOI: https://doi.org/10.1038/sj.cgt.7700791
Ee P.L., He X., Ross D.D., Beck W.T. „Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference” Molecular Cancer Therapy 2004, 3, 1577-1583 DOI: https://doi.org/10.1158/1535-7163.1577.3.12
Pichler A., Zelcer N., Prior J.L., Kuil A.J., Piwnica-Worms D. „In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein”, Clinical Cancer Research, 2005, 11, 4487–4494 DOI: https://doi.org/10.1158/1078-0432.CCR-05-0038
Kellen J.A. „The reversal of multidrug resistance: an update”, Journal of Experimental Therapeutics and Oncology, 2003, 3, 5–13 DOI: https://doi.org/10.1046/j.1359-4117.2003.01067.x
Shionoya M, Jimbo T, Kitagawa M, Soga T, Tohgo A. „DJ-927, a novel oral taxane, overcomes Pglycoprotein-mediated multidrug resistance in vitro and in vivo”, Cancer Science, 2003, 94(5), 459–466 DOI: https://doi.org/10.1111/j.1349-7006.2003.tb01465.x
Rose W.C., Fairchild C., Lee F.Y. „Preclinical antitumor activity of two novel taxanes”, Cancer Chemotherapy and Pharmacology, 2001, 47(2), 97–105 DOI: https://doi.org/10.1007/s002800000241
Kurata T., Shimada Y., Tamura T. „Phase I and pharmacokinetic study of a new taxoid, RPR 109881a, given as a 1-hour intravenous infusion in patients with advanced solid tumors”, Journal of Clinical Oncology, 2000, 18(17), 3164–3171 DOI: https://doi.org/10.1200/JCO.2000.18.17.3164
Perego P. „A novel 7-modified camptothecin analog overcomes breast cancer resistance proteinassociated resistance in a mitoxantrone-selected colon carcinoma cell line”, Cancer Research, 2001, 61, 6034–6037
Polizzi D., Pratesi G., Monestiroli S. „Oral efficacy and bioavailability of a novel taxane”, Clinical Cancer Research, 2000, 6(5), 2070–2074
Byrne J.L. „Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG”, Leukemia, 1999, 13, 786–791 DOI: https://doi.org/10.1038/sj.leu.2401406
Vail D.M. „Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies”, Seminars in Oncology, 2004, 31, 16–35 DOI: https://doi.org/10.1053/j.seminoncol.2004.08.002
Krishna R., St-Louis M., Mayer L.D. „Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin”, International Journal of Cancer, 2000, 85, 131–141 DOI: https://doi.org/10.1002/(SICI)1097-0215(20000101)85:1<131::AID-IJC23>3.0.CO;2-R
Fracasso P.M. „Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar”, British Journal of Cancer, 2005, 93, 46–53 DOI: https://doi.org/10.1038/sj.bjc.6602653
Blagosklonny M.V. „How cancer could be cured by 2015”, Cell Cycle, 2005, 4, 269–278 DOI: https://doi.org/10.4161/cc.4.2.1493
Lissianskaya A., Gershanovich M., Ognerubov N., Golubeva O., Pratt J. „Paclitaxel injectable emulsion: Phase 2a study of weekly administration in patients with platinum-resistant ovarian cancer”, Proc American Society of Clinical Oncology, 2004, 22:5047 DOI: https://doi.org/10.1200/jco.2004.22.90140.5047
Annereau J.P. „Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance”, Moleculer Pharmacology, 2004, 66, 1397–1405 DOI: https://doi.org/10.1124/mol.104.005009
Warr J R., Quinn D., Elend M., Fenton J.A. „Gain and loss of hypersensitivity to resistance modifiers in multidrug resistant Chinese hamster ovary cells” Cancer Letters, 1995, 98, 115–120 DOI: https://doi.org/10.1016/S0304-3835(06)80019-4
Trompier D. „Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1”, Cancer Research, 2004, 64, 4950–4956 DOI: https://doi.org/10.1158/0008-5472.CAN-04-0143
Bell S.E., Quinn D.M., Kellett G.L. Warr, J.R. „2-Deoxy-D-glucose preferentially kills multidrug-resistant human KB carcinoma cell lines by apoptosis”, British Journal of Cancer, 1998, 78, 1464–1470 DOI: https://doi.org/10.1038/bjc.1998.708
Johnstone R.W., Ruefli A.A., Smyth M.J. „Multiple physiological functions for multidrug transporter P-glycoprotein?”, Trends in Biochemical Sciences, 2000, 25, 1–6 DOI: https://doi.org/10.1016/S0968-0004(99)01493-0
Turzanski J., Grundy M., Shang S., Russell N., Pallis, M. „P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway”, Experimental Hematology, 2005, 33, 62–72 DOI: https://doi.org/10.1016/j.exphem.2004.10.005
Kontermann R.E. „Immunoliposomes for cancer therapy”, Current Opinion in Molecular Therapeutics, 2006, 8, 39–45
Stolnik S., Dunn S.E., Garnett M.C. „Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers”, Pharmaceutical Research, 1994, 11, 1800–1808
Peracchia M.T., Fattal E., Desmaele D. „Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting”, Journal of Controlled Release, 1999, 60, 121–128 DOI: https://doi.org/10.1016/S0168-3659(99)00063-2
Calvo P., Gouritin B., Chacun H. „Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery”, Pharmaceutical Research, 2001, 18, 1157–1166 DOI: https://doi.org/10.1023/A:1010931127745
Koo O.M., Rubinstein I., Onyuksel H. „Camptothecin in sterically stabilized phospholipid nanomicelles: a novel solvent pH change solubilization method”, Journal for Nanoscience and Nanotechnology, 2006, 6, 2996– 3000 DOI: https://doi.org/10.1166/jnn.2006.460
Lu J., Liong M., Zink J.I., Tamanoi F. „Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs”, Small, 2007, 3, 1341–1346 DOI: https://doi.org/10.1002/smll.200700005
Liang X., Chen C., Zhao Y., Wang P.C. „Circumventing Tumor Resistance to Chemotherapy by Nanotechnology”, Methods in Molecular Biology, 2010, 596, 467-488 DOI: https://doi.org/10.1007/978-1-60761-416-6_21
Wartlick H., Spankuch-Schmitt B., Strebhardt K., Kreuter J., Langer K. „Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles”, Journal of Control Release, 2004, 96, 483–495 DOI: https://doi.org/10.1016/j.jconrel.2004.01.029
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
